These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33290765)

  • 41. Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
    Liu B; Huang X; Hu Y; Chen T; Peng B; Gao N; Jin Z; Jia T; Zhang N; Wang Z; Jin G
    Oncotarget; 2016 Sep; 7(36):58038-58050. PubMed ID: 27487128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanomedicine of tyrosine kinase inhibitors.
    Smidova V; Michalek P; Goliasova Z; Eckschlager T; Hodek P; Adam V; Heger Z
    Theranostics; 2021; 11(4):1546-1567. PubMed ID: 33408767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting non-malignant disorders with tyrosine kinase inhibitors.
    Grimminger F; Schermuly RT; Ghofrani HA
    Nat Rev Drug Discov; 2010 Dec; 9(12):956-70. PubMed ID: 21119733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
    Wang R; Zhong C; Zhang C; Hua M; Ma D
    Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
    Abueg KD
    Clin J Oncol Nurs; 2014 Dec; 18(6):714-6. PubMed ID: 25427707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer.
    Korucu Aktas P; Baysal I; Yabanoglu-Ciftci S; Lamprecht A; Arica B
    Int J Pharm; 2024 Jan; 650():123703. PubMed ID: 38092263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
    Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
    Lee DH
    Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.